- Home
- CHRS vs FCEL Comparison
CHRS vs FCEL Comparison
Compare CHRS & FCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FCEL
- Stock Information
- Founded
- CHRS 2010
- FCEL 1969
- Country
- CHRS United States
- FCEL United States
- Employees
- CHRS N/A
- FCEL N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FCEL Industrial Machinery/Components
- Sector
- CHRS Health Care
- FCEL Energy
- Exchange
- CHRS Nasdaq
- FCEL Nasdaq
- Market Cap
- CHRS 112.5M
- FCEL 96.7M
- IPO Year
- CHRS 2014
- FCEL 1992
- Fundamental
- Price
- CHRS $0.78
- FCEL $5.11
- Analyst Decision
- CHRS Buy
- FCEL Hold
- Analyst Count
- CHRS 3
- FCEL 6
- Target Price
- CHRS $4.68
- FCEL $14.28
- AVG Volume (30 Days)
- CHRS 1.5M
- FCEL 1.2M
- Earning Date
- CHRS 05-12-2025
- FCEL 06-06-2025
- Dividend Yield
- CHRS N/A
- FCEL N/A
- EPS Growth
- CHRS N/A
- FCEL N/A
- EPS
- CHRS N/A
- FCEL N/A
- Revenue
- CHRS $272,251,000.00
- FCEL $114,438,000.00
- Revenue This Year
- CHRS N/A
- FCEL $42.70
- Revenue Next Year
- CHRS $19.78
- FCEL $10.61
- P/E Ratio
- CHRS $1.83
- FCEL N/A
- Revenue Growth
- CHRS 19.87
- FCEL 11.09
- 52 Week Low
- CHRS $0.66
- FCEL $3.58
- 52 Week High
- CHRS $2.43
- FCEL $30.90
- Technical
- Relative Strength Index (RSI)
- CHRS 40.90
- FCEL 56.75
- Support Level
- CHRS $0.74
- FCEL $4.04
- Resistance Level
- CHRS $0.82
- FCEL $5.84
- Average True Range (ATR)
- CHRS 0.07
- FCEL 0.53
- MACD
- CHRS -0.00
- FCEL 0.13
- Stochastic Oscillator
- CHRS 19.71
- FCEL 62.56
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FCEL FuelCell Energy Inc.
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products and electrolysis platforms that decarbonize power and produce hydrogen. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company operates in USA, South Korea, Europe and Canada. Majority of revenue is from USA and South Korea.